Drug Target Discovery Technology | Protein Interference


Phoremost’s technology aims to discover drug targets that remain intractable or undetected using conventional technologies, facilitating drug development for diseases such as cancer. Their novel SITESEEKER platform uses PROTEINi (or protein interference) – a new phenotypic screening method that identifies unexpected druggable sites that aren’t apparent with other technologies.

PROTEINi libraries encode millions of different proteins allowing identification of target-interaction sites throughout the whole proteome. This mechanism of action (MoA) animation shows how PROTEINi uses phenotypic screening to rapidly identify the key target-interaction sites involved in the disease being studied. This allows the discovery of novel drug targets including targets that were previously deemed ‘undruggable’.

This animation appears on the Phoremost technology page to showcase the potential of PROTEINi technology for drug discovery programs.

Are you interested in seeing how our award-winning medical animation can help you?

Random42 constantly strives to innovate in the medical animation space. Get in touch for a consultation on your next project.


cellectar logo

‘‘Extremely happy, everybody was great on the team. They answered all our questions and made it look easy. The end result is perfect.
Executive Coordinator, Cellectar Biosciences


‘‘The presentation was dramatically enhanced by the video, which looked fantastic on the big screen. Thank you and the entire Random42 team for your excellent work and for getting the final edition to me in time for the conference. All very much appreciated!
President and CEO, Vallum Corporation

‘‘It was a combination equally of quality of work but also the comfort and confidence that I knew I would be working with PhDs. They gave me the confidence that they would have the ability to understand. The other companies didn’t have those sorts of people on staff, they were just good animators. That was the area where I felt that I could trust Random42 would deliver.’’
Senior Product Manager, Spectranetics

Amgen Logo

‘‘I have been to a lot of conferences and I have seen a lot of videos both from competitors and internally – in my eyes it is night and day. The quality Random42 have is not one step ahead, it is far ahead compared to what I have seen before.’’
Product Manager, Amgen